Recommended therapeutic options for the management of venous thromboembolism (VTE) in patients with cancer are burdensome, and compliance guidelines is unknown.To describe current treatment patterns to evaluate patient persistence on various anticoagulants.Medical pharmacy claims from Humana Database were analyzed (01/2007-12/2014). Newly diagnosed treated anticoagulants categorized into one following cohorts: low-molecular-weight heparin (LMWH), warfarin, rivaroxaban. Discontinuation,...

Abstract Anticoagulation is used to treat venous thromboembolism (VTE) in cancer patients, but may be associated with an increased risk of bleeding. VTE recurrence and major bleeding were assessed patients treated for the most currently prescribed anticoagulants clinical practice. Newly diagnosed (first 1/1/2013‐05/31/2015) who initiated rivaroxaban, low‐molecular‐weight heparin (LMWH), or warfarin identified from Humana claims data observed until end eligibility availability. was a...

Abstract Background Stroke severity is an important predictor of patient outcomes and commonly measured with the National Institutes Health Scale (NIHSS) scores. Because these scores are often recorded as free text in physician reports, structured real-world evidence databases seldom include severity. The aim this study was to use machine learning models impute NIHSS for all patients newly diagnosed stroke from multi-institution electronic health record (EHR) data. Methods available Optum©...

Objective: This study was designed to evaluate the postimpact response of articular cartilage in rabbit knee after a single traumatic episode. Design: A novel servo-controlled Rabbit Impact Test System (RITS) developed apply well-defined trauma femoral condyle knee. The RITS first used an vitro determine appropriate stress cause damage without bone fracture. Viable knees (n = 18) were impacted with stresses 15 50 MPa at rate 420 MPa/s, latter corresponding joint impact rates commonly seen...

Background and Purpose- Oral anticoagulation therapy is standard of care for patients with nonvalvular atrial fibrillation to prevent stroke. This study compared rivaroxaban warfarin stroke all-cause mortality risk reduction in a real-world setting. Methods- retrospective cohort (2011-2017) included de-identified from the Optum Clinformatics Database who started treatment or within 30 days following initial diagnosis fibrillation. Before diagnosis, had 6 months continuous health plan...

Abstract Background The Khorana score (KS) clinical algorithm is used to predict VTE risk in cancer patients. study objective was evaluate and survival rates among patients newly diagnosed with stratified by KS a real‐world population. Methods Data from the Optum ® Clinformatics DataMart database between 01/01/2012–09/30/2017 identify adults ≥ 1 hospitalization or 2 outpatient claims diagnosis (index date). Only who were initiated on chemotherapy radiation therapy included. Patients...

Background:Few studies have addressed the cost patterns of patients with multiple myeloma (MM) before and after first relapse. This US claims analysis evaluated, from a health plan perspective, total direct costs care treatment initiation to progression for MM treated novel agents, using time next therapy (TTNT) as proxy measure progression.Methods:A retrospective study was conducted large database, evaluating between 2006 2013. Patients stem cell transplant (SCT) were excluded. The focused...

Background: Although rivaroxaban has demonstrated consistent drug levels in normal weight and obese patients, sufficient confirmation of equal clinical effectiveness safety is currently lacking.Purpose: To evaluate the versus warfarin for prevention stroke systemic embolism (SSE) nonvalvular atrial fibrillation (NVAF) patients.Methods: Using Optum de-identified Electronic Health Record (EHR) data from November 2011 to September 2018,we evaluated NVAF patients with a body mass index (BMI)≥30...

The objective of this study was to assess mechano-biological response articular cartilage when subjected a single impact stress. Mature bovine explants were impacted with peak stresses ranging from 10 60 MPa at stress rate 350 MPa/s. Water loss, matrix axial deformation, dynamic modulus (DIM), and cell viability measured immediately after impaction. water loss through the surface (AS) small ranged 1% 6% increasing corresponding strains 2.5% 25%, respectively, while DIM 455.9±111.9 MPa....

Background Autologous osteochondral transplantation surgery requires an impact force on the graft that may cause chondrocyte death and matrix degradation. This study attempted to determine degree which this occurs in a rabbit model shortly after procedure. Hypothesis Impaction of press-fit autologous vivo results necrosis, apoptosis, degradation at early time points. Study Design Controlled laboratory study. Methods Twenty New Zealand White rabbits underwent unilateral (OT) surgeries, 10,...

Introduction: Rivaroxaban has been shown to have similar efficacy but less major bleeding than warfarin in randomized trials of patients experiencing venous thromboembolism (VTE). This report sought assess healthcare costs up 12-months following an index VTE prescribed either rivaroxaban or warfarin.Materials and methods: study analyzed claims from the MarketScan Commercial Claims Encounters Database November 2011–July 2015. It selected adults newly-diagnosed with (deep vein thrombosis [DVT]...

Objective: The standard of care for cancer-related venous thromboembolism (VTE) has been low molecular weight heparin (LMWH), but oral anticoagulants are also widely prescribed. This study compared VTE-related healthcare resource utilization and costs cancer patients treated with anticoagulants. Methods: Claims data from Humana Database (January 1, 2013-May 31, 2015) were analyzed. Based on the first anticoagulant received, classified into LMWH, warfarin, or rivaroxaban cohorts....

Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some patients experience cardiovascular complications, including thromboembolic events and death. Data needed to better inform prevention treatment these events. This analysis was designed describe patient characteristics, medication use, events, all-cause mortality in hospitalized COVID-19 the United States. Methods retrospective, observational cohort study identified adults with (January 21, 2020-January 07, 2021)...

Anticoagulant therapy for at least 3–6 months is currently recommended treatment of venous thromboembolism (VTE) in patients with cancer, but the optimal duration unknown. This study examines association between anticoagulation and VTE recurrence cancer patients. The Humana claims database was used to identify newly diagnosed who had their first diagnosis January 1, 2013, May 31, 2015, initiated injectable or oral anticoagulant therapy. Follow-up calculated from index initiation end...

BackgroundPer treatment guidelines, resistant hypertension is defined as uncontrolled blood pressure (BP) while taking 3 concomitant antihypertensives (AHTs) or controlled BP ≥4 AHTs. Characteristics, AHT therapy use, and control were analyzed in US patients with who prescribed ≥3 classes of medications.MethodsThis retrospective analysis the Optum® Electronic Health Record Database evaluated ≥18 years age a diagnosis classified based on number medication (3, 4, ≥5). For primary analysis, was...

Objective: Patients with cancer are at high risk for developing primary but also recurrent venous thromboembolism (VTE). This study examined healthcare utilization (HRU) and costs related to VTE recurrence among patients.Methods: Medical pharmacy claims from the Humana Database were used compare HRU (outpatient visits, emergency room hospitalizations, hospitalization days) patients a single event (between 01/2013 06/2015) those during follow-up period (from initiation of anticoagulant...

Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 (01/21/2020-01/07/2021) using de-identified Optum ® Electronic Health Records data. Patient characteristics, occurrence of TEEs, all-cause mortality, anticoagulant or thrombolytic medication use were evaluated. Of 1,246,067 patients diagnosis, 141 471 met entry criteria. Mean...

Peripheral artery disease (PAD), often treated with lower extremity revascularization, is associated risk of major atherothrombotic vascular events (acute limb ischemia [ALI], non-traumatic lower-limb amputation, myocardial infarction [MI], ischemic stroke, cardiovascular death). This study aims to assess healthcare resource utilization and costs such among patients PAD after revascularization. Patients aged ≥50 years who were lower-extremity revascularization identified from Optum...